Adult outpatients with chronic and/or recurrent MDD were randomly assigned in 1:1:1 ratio to 28 weeks of single-blind , placebo-controlled antidepressant treatment with ( 1 ) escitalopram + placebo , ( 2 ) bupropion-sustained-release + escitalopram , or ( 3 ) venlafaxine-extended-release + mirtazapine .